Pharma
Sandoz International GmbH
3
Articles
Deal Party
Top Role
Apr 7, 2026
First Mention
Apr 11, 2026
Last Mention
2.82
Relevance Score
Coverage Timeline
April 2026
Biosimilars Beyond Humira: New Pressures and Unwritten Rules for Stelara, Keytruda, and Eylea in 2026
Pipeline
Deal Party
Apr 11, 2026
Fresenius Kabi, Sandoz, and Amgen are all chasing pembrolizumab biosimilars.
Apr 11, 2026
Enbrel’s US exclusivity, once locked through 2029 by an aggressive defense, is now vulnerable after the Supreme Court declined to review Sandoz’s latest bid.
Novartis Spins Off Sandoz: What the $10B Pure-Play Means for Biosimilar Strategies and Drug Pricing 2025-2026
Deals
Primary Subject
Apr 7, 2026
The Sandoz spin-out, delivered as an all-share distribution and valued at roughly $10.5 billion.